All In MedTech

FDA Clearance Tracker · K171753

BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Jul 21, 2017

Substantially Equivalent

Time to decision

39 days

Received Jun 12, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Special

Device class

Class II

The decision

FDA number
K171753
Device name
BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16
Applicant location
Newcastle Upon Tyne, GB
Received
Jun 12, 2017
Decided
Jul 21, 2017
Decision
Substantially Equivalent
Submission type
Special

Device type

Device class
Class II
Regulation
21 CFR 864.1860

Every decision under product code MXZ

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MXZ. The earliest in FDA's data is K990618, decided Jul 23, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

  • FDA database record for K171753
  • The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Leica Biosystems Newcastle, Limited

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.